Belgium Stops JNJ COVID-19 Vaccine For Under 41 Years After One Death: Reuters

Belgium is suspending vaccinations with Johnson & Johnson's JNJ COVID-19 vaccine for people under the age of 41 following the death of a woman from severe side effects after receiving the shot.
"The Inter-ministerial conference has decided to temporarily administer Janssen's vaccine to the general population from the age of 41 years, pending a more detailed benefit-risk analysis by the EMA," said a statement issued by Belgium's federal health minister and seven regional counterparts.
There was no immediate comment from the European Medicines Agency or J&J.
Reuters reports that a woman below 40 died after being hospitalized with severe thrombosis and platelet deficiency.
Belgium has administered about 40,000 J&J shots, with 80% of those to people over 45 years old, the statement said.
J&J has said that no clear causal relationship has been established between the clots.
Last month, the EMA found a possible link between the vaccine and rare blood clotting issues but backed its overall benefits against any risks.
Belgium has asked for advice from the EMA to evaluate the connection between the woman's death and the J&J vaccine.
It did not say when it expected EMA's final opinion on it.
Price Action: JNJ shares are down 0.37% at $169.45 during the market session on the last check Wednesday.

Momentum60.24

Growth63.43

Quality13.55

Value22.79

Short

Medium

Long